<DOC>
	<DOCNO>NCT02956226</DOCNO>
	<brief_summary>This study aim assess safety , tolerability efficacy cannabinoids mix [ cannabidiol ( CBD ) , Δ9-tetrahydrocannabinol ( THC ) 20:1 ratio ] behavioral problem child youth ASD .</brief_summary>
	<brief_title>Cannabinoids Behavioral Problems Children With ASD</brief_title>
	<detailed_description>Disruptive behavior common child youth autism spectrum disorder ( ASD ) . Behavioral problem increase social impairment child ASD , make intervention difficult place considerable strain family caregiver . Current treatment base behavioral intervention combine atypical antipsychotic often low tolerability questionable efficacy . Cannabis exert profound effect human social behavior . Research use animal model ASD indicate possible dysregulation endocannabinoid system , stress may novel target pharmacological intervention . Anecdotal evidence suggest efficacy various phytocannabinoids resistant behavioral problem . However control human study lack . Objective : To assess safety , tolerability efficacy cannabinoids mix [ cannabidiol ( CBD ) , Δ9-tetrahydrocannabinol ( THC ) 20:1 ratio ] behavioral problem child youth ASD . Setting : A double blind randomize placebo-controlled trial crossover . Methods : One hundred twenty participant age 6-30 year , establish ASD diagnosis moderate severe refractory behavioral problem treat placebo cannabinoids mix randomize cross-over trial . Each intervention period 12 week additional 4 week gradual dose decrease wash-out . Baseline evaluation include : Autism diagnostic observation schedule ( ADOS-2 ) , Social Communication Questionnaire ( SCQ ) , Vineland II ( interview base ) , Childhood Autism Rating Scale ( CARS-2 , observation base ) . Primary outcome measure : Home Situations Questionnaire-Autism Spectrum Disorder ( HSQ-ASD ) , Child Behavior Checklist ( CBCL , parent-rated ) , Autism Parenting Stress Index ( APSI ) assess every 4 week . Secondary outcome measure : Clinical Global Impression ( CGI , improvement efficacy index item , clinician-rated ) Social Responsiveness Scale ( SRS , parent teacher rat ) assess baseline termination treatment period . Adverse event tap every 4 week .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>( need ) ASD diagnosis ( Diagnostic Statistical Manual Mental Disorders [ Fifth Edition ; DSMV ] Moderate great behavioral problem measure rating moderate high ( ≥4 ) Clinical Global ImpressionSeverity ( CGIS ) Planned change exist intervention duration trial change last 4 week . Current treatment cannabis base therapy treatment last 3 month . Heart , liver , renal hematological disorder History psychotic disorder first degree relative .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>